Fluoride

Fluoride

SCHEMBL2551493

F.F.c1ccc(P(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.92

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.92
CYP3A4 P08684 1/20 0.92
ESR1 P03372 4/20 0.63
ESR2 Q92731 4/20 0.63
KDM4E B2RXH2 1/20 0.48
GAA P10253 1/20 0.48
ALDH1A1 P00352 4/20 0.38
NPSR1 Q6W5P4 1/20 0.37
DRD1 P21728 2/20 0.35
TSHR P16473 4/20 0.33
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA9 Q16790 2/20 0.33
LMNA P02545 2/20 0.33
CA12 O43570 1/20 0.33
GLA P06280 1/20 0.33
CA3 P07451 1/20 0.33
CA4 P22748 1/20 0.33
CA14 Q9ULX7 1/20 0.33
ALOX12 P18054 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluoride SCHEMBL1149822 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
Fluoride SCHEMBL28990450 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
Fluoride SCHEMBL9231618 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
Fluoride SCHEMBL9231621 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
Fluoride SCHEMBL2551489 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
Fluoride SCHEMBL1149824 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
Fluoride SCHEMBL6035605 1.00 TDP1 (0.92) TDP1CYP3A4ESR1ESR2KDM4E
Fluoride SCHEMBL28374524 0.96 TDP1 (0.86) TDP1CYP3A4ESR1ESR2KDM4E
Fluoride SCHEMBL27778936 0.96 TDP1 (0.86) TDP1CYP3A4ESR1ESR2KDM4E
Fluoride SCHEMBL27764146 0.96 TDP1 (0.86) TDP1CYP3A4ESR1ESR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735629-B2 Process for the reduction of a tertiary phosphine oxide to the corresponding tertiary phosphine in the presence of a catalyst and use of a tertiary phosphine for reducing a tertiary phosphine oxide in the presence of a catalyst CHROMAFORA AB (SE) 2014-05-27 US claimed
US-10815258-B2 Phosphine oxides reduction RHODIA OPERATIONS (FR) 2020-10-27 US disclosed
US-20200231613-A1 PHOSPHINE OXIDES REDUCTION SPECIALTY OPERATIONS FRANCE (FR) 2020-07-23 US disclosed
EP-3347364-A1 PHOSPHINE OXIDES REDUCTION Rhodia Operations (FR) 2018-07-18 EP disclosed
WO-2017041250-A1 PHOSPHINE OXIDES REDUCTION RHODIA OPERATIONS (FR) 2017-03-16 WO disclosed
WO-2017041723-A1 PHOSPHINE OXIDES REDUCTION RHODIA OPERATIONS (FR) 2017-03-16 WO disclosed
CN-102947319-B Method and tertiary phosphine for phosphine oxides is reduced into corresponding tertiary phosphine in the presence of a catalyst is used for reducing in the presence of a catalyst the purposes of phosphine oxides 克罗马福拉公司 2016-11-09 CN disclosed
CN-105102417-A Method for producing 4-halosenecioic acid derivative SAGAMI CHEMICAL RES INST 2015-11-25 CN disclosed
EP-2552928-B1 A PROCESS FOR THE REDUCTION OF A TERTIARY PHOSPHINE OXIDE TO THE CORRESPONDING TERTIARY PHOSPHINE IN THE PRESENCE OF A CATALYST AND USE OF A TERTIARY PHOSPHINE FOR REDUCING A TERTIARY PHOSPHINE OXIDE IN THE PRESENCE OF A CATALYST. CHROMAFORA AB (SE) 2015-04-15 EP disclosed
US-8735629-B2 Process for the reduction of a tertiary phosphine oxide to the corresponding tertiary phosphine in the presence of a catalyst and use of a tertiary phosphine for reducing a tertiary phosphine oxide in the presence of a catalyst CHROMAFORA AB (SE) 2014-05-27 US disclosed
US-8426647-B2 2013-04-23 US disclosed
CN-102947319-A A process for the reduction of a tertiary phosphine oxide to the corresponding tertiary phosphine in the presence of a catalyst and use of a tertiary phosphine for reducing a tertiary phosphine oxide in the presence of a catalyst CHROMAFORA AB 2013-02-27 CN disclosed
EP-2552928-A1 A PROCESS FOR THE REDUCTION OF A TERTIARY PHOSPHINE OXIDE TO THE CORRESPONDING TERTIARY PHOSPHINE IN THE PRESENCE OF A CATALYST AND USE OF A TERTIARY PHOSPHINE FOR REDUCING A TERTIARY PHOSPHINE OXIDE IN THE PRESENCE OF A CATALYST Chromafora AB (SE) 2013-02-06 EP disclosed
US-20130012725-A1 PROCESS FOR THE REDUCTION OF A TERTIARY PHOSPHINE OXIDE TO THE CORRESPONDING TERTIARY PHOSPHINE IN THE PRESENCE OF A CATALYST AND USE OF A TERTIARY PHOSPHINE FOR REDUCING A TERTIARY PHOSPHINE OXIDE IN THE PRESENCE OF A CATALYST CHROMAFORA AB (SE) 2013-01-10 US disclosed
US-20120172208-A1 METHODS FOR SILVER PROMOTED FLUORINATION OF ORGANIC MOLECULES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2012-07-05 US disclosed
US-8212090-B2 Methods for silver-promoted fluorination of organic molecules THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2012-07-03 US disclosed
WO-2011123037-A1 A PROCESS FOR THE REDUCTION OF A TERTIARY PHOSPHINE OXIDE TO THE CORRESPONDING TERTIARY PHOSPHINE IN THE PRESENCE OF A CATALYST AND USE OF A TERTIARY PHOSPHINE FOR REDUCING A TERTIARY PHOSPHINE OXIDE IN THE PRESENCE OF A CATALYST CHROMAFORA AB (SE) 2011-10-06 WO disclosed
US-20100152502-A1 METHODS FOR SILVER-PROMOTED FLUORINATION OF ORGANIC MOLECULES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2010-06-17 US disclosed
CN-1263882-A Method for preparing fluorine-substituted aromatic compound MITSUI CHEMICALS INC (JP) 2000-08-23 CN disclosed
EP-1013629-A1 Preparation process of fluorine subsituted aromatic compound Mitsui Chemicals, Inc. (JP) 2000-06-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10815258-B2 Phosphine oxides reduction PHOSPHO1, PSPH, PTEN TDP1 2897/4885CYP3A4 2013/4885ESR1 1948/4885
US-20130012725-A1 PROCESS FOR THE REDUCTION OF A TERTIARY PHOSPHINE OXIDE TO THE CORRESPONDING TERTIARY PHOSPHINE IN THE PRESENCE OF A CATALYST AND USE OF A TERTIARY PHOSPHINE FOR REDUCING A TERTIARY PHOSPHINE OXIDE IN THE PRESENCE OF A CATALYST PSPH, PNPO, PHOSPHO1 TDP1 1944/4885CYP3A4 1008/4885ESR1 3033/4885
US-20200231613-A1 PHOSPHINE OXIDES REDUCTION PHOSPHO1, PSPH, PTEN TDP1 2897/4885CYP3A4 2013/4885ESR1 1948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.